Due to its 3 carbonic acid groups available for bioconjugation, the TRAP chelator (1,4,7-triazacyclononane-1,4,7-tris(methylene(2-carboxyethylphosphinic acid)) is destined for synthesis of trimeric bioconjugates for radiolabelling. We optimized a protocol for bio-orthogonal TRAP conjugation via Cu(I)-catalyzed Huisgen-cycloaddition of terminal azides and alkynes (CuAAC), including a detailed investigation of kinetic properties of Cu(II)-TRAP complexes. TRAP building blocks for CuAAC, TRAP(alkyne) 3 and TRAP(azide) 3 , were obtained by amide coupling of propargylamine / 3-azidoprop-1-ylamine, respectively. For Cu(II) complexes of neat and triply amidefunctionalized TRAP, the equilibrium properties as well as pseudo-first-order Cu(II)-transchelation, using 10-to 30 eq of NOTA and EDTA, were studied by UV-spectrophotometry. Dissociation of any Cu(II)-TRAP species was found independent from the nature or excess of competing chelator, confirming a proton-diven two-step mechanism. The respective thermodynamic stability constants 
Introduction
Today, functional molecular imaging is an indispensable part of personalised healthcare. Integrated scanners for simultaneous spatial mapping of morphology / anatomy as well as functional aspects, such as metabolism or receptor expression, have experienced a particularly dynamic evolution in recent years. Their high value for medical diagnostics is rooted in an outstanding superposition (registration) of functional and anatomical images, allowing for precise localisation and functional analysis of lesions and, subsequently, individual planning of tailored therapies. While integration of functional nuclear imaging, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), with computed tomography (CT) has already become clinical standard, 1 the new possibilities associated with the recent combination of PET with magnetic resonance imaging (MRI) into a full-body scanner have thrilled both researchers and medical practitioners, 2,3,4 not least because MRI can also provide various functional information. Since a comparable progress is currently observed for small-animal imaging devices, multimodal 3D-imaging becomes more and more attractive for preclinical research and life sciences in general. Here, optical methods, 5 such as fluorescence/luminescence, 6 cerenkov 7, 8 or photoacoustic 9 imaging, play an important role as well, because the smaller size of investigated subjects is compatible with the limited penetration depth of light. With multi-purpose small animal scanners, meaningful and compelling invivo data can be obtained quickly, thus saving time and money in medical and pharmaceutical development.
As the capabilities of functional imaging are primarily determined by the performance and diversity of the corresponding probes, efforts directed at suitable tracers have been increased in recent time. In terms of PET tracers, this development is further promoted by the fact that some medically useful positron-emitting metal radionuclides have recently become widely available, such as 89 Zr, 10 64 Cu, 11 and 68 Ga. 12, 13 Of these, gallium-68 is particularly attractive for preclinical and translational research, because it is obtained from 68 Ge/ 68 Ga-radionuclide generators with a very long shelf life (up to 1 year). 14, 15, 16, 17, 18 Such a generator can be eluted several times a day, resulting in low radionuclide costs per experiment, particularly for high workload. Structures to be labelled are usually conjugates of biomolecules with a chelator, into which ionic 68 Ga III is introduced simply by complex formation.
Compared to most traditional syntheses of 11 C-or 18 F-labelled compounds, such one-step 68 Garadiolabelling procedures are generally fast (10-15 min) and quite similar for different compounds. In almost all cases, slightly adjusted standard protocols can be applied, for which purpose a wide range of automated 68 Ga-labelling modules (including technical support) are commercially available. 19 In other words, the key challenge in making a 68 Ga radiopharmaceutical consists in synthesising the desired chelator conjugate as a precursor-for the rest, out-of-the-box solutions are at hand.
In view of these prospects, recent years have seen a variety of novel 68 Ga chelators, optimised for efficient labelling and facile bioconjugation. 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 We proposed 1,4,7-triazacyclononane-1,4,7-tris(2-carboxyethyl-methylenephosphinic acid) (TRAP, Scheme 1) as a suitable platform for elaboration of 68 Ga radiopharmaceuticals. 31, 32, 33, 34 Apart from the fact that this compound shows high efficiency in Ga III complexation 35, 36 and possesses unique selectivity for Ga III ion, 37 its symmetrical structure with three carboxylic acid moieties not involved into complex formation allows for decoration with up to three functional molecules, such as peptide receptor ligands, fluorophors, other metal binding structures, and more. 35, 38, 39, 40, 41 Hence, TRAP is destined for straightforward design of radiolabelled homo-or heteromultimeric conjugates, obviating the need for branching linkers or additional multimeric scaffolds.
During first attempts to synthesise TRAP-based multimeric conjugates by amide formation, it was observed that common peptide coupling protocols, consisting of transformation of carboxylates into active esters and subsequent reaction with an amine, can not be applied without modification. This is because active esters of TRAP are not stable in the long term, which is probably related to the close proximity of the phosphinate moieties. We found that the problem can be solved by using excess amine and adding a uronium-type coupling reagent as the last component. 32 Clearly, this approach prohibits the presence of certain functional groups in substrates, particularly carboxylic acids and aliphatic alcohols. Consequently, such substrates must be appropriately protected, which, at best, might be just inconvenient, but can also turn out to be a rather complicated task. An obvious workaround consists in using a different coupling chemistry. In a proof-of-principle experiment employing the propargylamine conjugate TRAP(alkyne) 3 (Scheme 1), we have already shown that the Cu II -catalyzed 1,3-bipolar Huisgen cycloaddition of terminal alkynes and azides (commonly dubbed "click chemistry") 42 can be applied, 35 with the major drawback that the reaction yields the copper complexes of the conjugates. Although the copper ion could be removed from the chelate cage with sulfide, this method spoiled the product with colloidal copper sulfide precipitates, severely perturbing workup. Furthermore, sulfide is a reducing agent and cleaves disulfide bridges, further limiting the method's scope of application. Another common method, the demetallation with cyanide, is not attractive as well. The use of this highly toxic reagent is disfavoured in the last synthetic step towards pharmaceutical grade compounds, for it might complicate release procedures in a GMP production setting because absence of traces of free cyanide were to be proven and certified for each batch.
Since a solution for all these problems was expected to substantially expand the field of application for TRAP, and thus pave the way towards a great variety of useful PET tracers, we set out to establish a simple and robust protocol for click chemistry functionalisation. Furthermore, we found that the reaction was completed after 30 min in many solvents, namely methanol, ethanol, 2-propanol, DMSO, 1,4-dioxane, and aqueous mixtures thereof. We noted that in pure acetonitrile, formation of an emulsion was observed, resulting in an incomplete reaction. This points at the fact that solubility of all components, that is, reactants and intermediates of the stepwise conjugation, is recommended to ensure a smooth reaction, rendering the choice of solvent of key importance.
Altogether, the "click trimerisation" based on TRAP(alkyne) 3 is best conducted using a small excess of azide (3.3 eq) and Cu II (1.2 eq), as well as a generous allowance of sodium ascorbate (> 10 eq.), and can be performed in a wide variety of polar solvents or (aqueous) solvent mixtures. We found that under optimal conditions (pure starting compounds, no precipitation of any component during the reaction), turnover is virtually quantitative in less than one hour, and only the trimer and traces of residual azide substrate are observed in the reaction control (HPLC). Finally, we also prepared the corresponding TRAP derivative with opposite Huisgen functionality, TRAP(azide) 3 (Scheme 1), to broaden the scope of the method by enabling trimerisation of biological vectors with alkyne groups as well.
Solution thermodynamics
Although the structure of any bifunctional chelator is changed in the course of conjugation, the associated effects on thermodynamic stability and kinetic inertness of metal complexes often receive little attention. Apart from the obvious impact of modifications directly at the chelating unit, such as the conversion of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) to DOTAmonoamide 46 upon synthesis of DOTA-conjugates, 47 conjugation on distal functional groups is widely regarded to have no significant consequences.
Scheme 2: Structural formula of TRAP(CHX) 3 However, since kinetic inertness of complexes is essentially determined by competitive interaction of metal ions and protons with the ligand's donor atoms, we considered it to be of relevance that TRAP possesses three carboxylates located near the chelating moiety, acting as proton acceptors, which are not present in the respective conjugates. Hence, thermodynamic and kinetic studies were performed for TRAP as well as for TRAP(CHX) 3 32 (Scheme 2), serving as a model for trimeric TRAP conjugates. Table 2 ). The same trend is observed for other divalent metal ions, further substantiating the notion of a different behaviour of TRAP and its conjugates. 
Kinetic inertness & transchelation
In order to establish a procedure for removal of Cu II from TRAP conjugates, we investigated transchelation of Cu II towards two chelators with known suitability for Cu II coordination, namely EDTA and NOTA. 52 Reactions were monitored by means of UV spectrophotometry at the absorption bands of Cu(EDTA) and Cu(NOTA) complexes over a pH range of 1.7-4, using 10-30 eq. of EDTA or NOTA, respectively, and kinetic parameters calculated from these data (see Supplemental information). Figure 1 shows that the obtained pseudo-first-order rate constants at 298 K are independent from the identity or excess of the competing chelator, and increase with sinking pH. Consequently, the transchelation is recognised as a three-step process, initiated by protonation of the complex and followed by its spontaneous dissociation as the rate-determining step, whereafter free Cu In order to gain further insight into the underlying reaction mechanisms and the species involved, pseudo-first-order rate constants were measured at various temperatures over the range of 288-323 K, and the Eyring activation parameters were calculated for complex species with different protonation status ( , contribute most to dissociation in acidic media. Since these species are, according to their aforementioned protonation constants in the range of 1.6 to 1.9, highly abundant at pH 1.5, and their activation parameters are identical with respect to the error margins (Table 3) , the observed levelling of the overall dissociation rate constants below pH 2 ( Figure 1 ) is well explained. Figure 1 ) and, therefore, the increased stability of the conjugate complexes. The pH-dependent half lives of dissociation, calculated and extrapolated on the basis of equilibrium and kinetic data, finally allow to draw some important conclusions. Figure 3 (Table 2) , providing a strong driving force for the entire reaction. Second, the protonated complex [Cu(HNOTA)] is kinetically inert, 52 meaning that it does not show a tendency towards spontaneous dissociation like Cu(EDTA) or the phosphinate complexes. We found that demetallation of Cu II -containing TRAP conjugates could be achieved by adding NOTA directly to the reaction mixture and adjusting the pH to 2-3 with dilute HCl, once the click coupling is finished. In practice, addition of NOTA trihydrochloride has been found to be most convenient, since the NOTA-bound HCl readily adjusts the pH of the solution to the required acidic range, obviating the need for any further reagent. Altogether, the favorable properties of NOTA justify its application despite the high price, as this is of secondary importance in view of the micromolar amounts of substrates commonly handled during synthesis of precursors for radiolabelling.
In order to demonstrate the utility and convenience of the devised one-pot procedure, it was applied for synthesis of a trimeric conjugate of DUPA-Pep which otherwise would have been much more difficult to obtain (Scheme 4). DUPA-Pep 57 is a urea-type enzyme inhibitor which has earlier been labelled with 99m Tc and used for in-vivo SPECT imaging of prostate-specific membrane antigen (PSMA, EC 3.4.17.21, synonyms: glutamate carboxypeptidase II, NAALADase), 58 a hydrolytic zinc enzyme that is overexpressed by human prostate cancers. 59 For trimerisation, a terminal azide was introduced by standard peptide coupling in solution, using pre-activated 5-azidopentanoic acid as building block. Now, the trimer was synthesised applying our two-step, one-pot procedure (Scheme PET images were acquired for both 68 Ga-labelled compounds, with CD-1 athymic nude mice bearing LNCaP xenografts on the right shoulder as subjects. Figure 4 shows that trimerisation resulted in substantially increased tumor uptake, accompanied by lower background. However, in this particular case, the increased tumor-to-background ratio most probably does not only rely on improved target affinity. According to recent literature, the poor performance of the monomer is owed to degradation of DUPA-Pep in vivo, which, in turn, is rooted in metabolic instability of the L-Phe-L-Phe structural motif. 60 Interconnection of several of these unstable moieties in 68 Ga-TRAP(DUPA-Pep) 3 most likely results in a prolonged time for complete loss of targeting properties of the entire construct, as more than one metabolic cleavage per radiolabel is required. This might be the reason for the superior retention of activity at the target, observed for 68 Ga-TRAP(DUPA-Pep) 3 . This finding is of particular interest, because it suggests that it might be generally possible to obtain useful (radio)pharmaceuticals from metabolically unstable targeting molecules by means of multimerisation. However, confirmation of this hypothesis certainly requires more such multimers as examples, the synthesis of which could be greatly facilitated using the TRAP platform and applying our one-pot click chemistry protocol. 
Conclusion
The opposing trends of thermodynamic stability and kinetic inertness, observed for the Cu II complexes of TRAP and TRAP-conjugates, are another example for the generally known but frequently unheeded fact that equilibrium constants are of little predictive value concerning kinetic inertness, and thus, invivo stability, of metal complexes. For example, similar observations have been desecibed recently for Cu(II) complexes of cyclam-based di-phosphinates and di-phosphonates. 61 We thus like to emphasise again that for a valid interpretation or prognosis of in-vivo behaviour, investigation of fundamental kinetics is of key importance. In addition, our results illustrate that modifications on remote functional groups (i.e., conjugation sites) of a given bifunctional chelator can significantly affect the metalbinding properties of its primary coordination site.
In this respect, our data corroborate and explain a previous study on the stability of some 64 Cu-labelled 
Experimental
A complete and detailed description of materials and methods is provided as supplementary information, while a brief account is given in the following. TRAP 32 was prepared as described.
TRAP(CHX) 3 , 32 TRAP(alkyne) 3 35 and TRAP(azide) 3 were prepared according to a published procedure, 32 by employing a modified peptide coupling protocol (reagent: HATU, base: DIPEA, solvent: DMSO) and the respective amines (cyclohexylamine, propargylamine, 3-azidopropylamine).
DOTAGA-DUPA-Pep was prepared from commercial DUPA-Pep and decorated with DOTAGA using DOTAGA-anhydride. 72 Equilibrium studies (protonation and stability constants) were performed by pH-potentiometry, UV- 44 This procedure is readily transferable to clinical settings. 73 PET imaging was done on a Siemens Inveon small animal PET system as described. 35 Approx. 12 MBq of 68 Ga-DOTAGA-DUPA-Pep (≈ 0.3 nmol) or 68 Ga-TRAP(DUPA-Pep) 3 (≈ 0.15 nmol) respectively, were administered to CD-1 athymic nude mice bearing LNCaP xenografts on the right shoulder. PET data were acquired 60 min p.i. for 15 min, and images reconstructed by OSEM3D algorithm.
